Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Scilex Holding Company (SCLXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: SCLXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.83% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.14 | 52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 |
52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4990167 |
Shares Outstanding - | Shares Floating 4990167 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company was founded in 2017. It emerged as a pharmaceutical company focused on developing and commercializing non-opioid pain management treatments. A significant milestone was its spin-off from Sorrento Therapeutics in 2021 and subsequent listing on the Nasdaq stock exchange. The company has been actively building its portfolio through strategic acquisitions and in-licensing agreements.
Core Business Areas
- Pain Management Pharmaceuticals: Scilex's primary focus is on the development and commercialization of prescription pain management products, with a strong emphasis on non-opioid alternatives. Their strategy involves identifying unmet needs in pain treatment and bringing innovative solutions to market.
- Adoption of AI in Drug Development: The company is exploring the integration of artificial intelligence (AI) in various aspects of its operations, including drug discovery, clinical trial optimization, and patient stratification, to accelerate development timelines and improve success rates.
Leadership and Structure
Scilex Holding Company is led by a management team with experience in the pharmaceutical industry. The exact organizational structure is typical of a publicly traded pharmaceutical company, with departments for research and development, commercial operations, regulatory affairs, finance, and administration.
Top Products and Market Share
Key Offerings
- Ztlido (lidocaine topical system): Ztlido is a prescription lidocaine topical system indicated for the relief of postherpetic neuralgia (PHN). It is a transdermal delivery system designed for localized pain relief. Competitors include other topical pain relief medications such as lidocaine patches from companies like AbbVie (Qutenza) and generic lidocaine preparations. Market share data for Ztlido specifically is not publicly disclosed, but the topical analgesic market is substantial.
- Fujirebio Diagnostics: Scilex has a commercial agreement with Fujirebio Diagnostics, Inc. to market and distribute their Lumipulseu00ae G immunoassay testing platform and related assays in the United States and Europe. This segment focuses on diagnostic solutions, diversifying Scilex's revenue streams. Market share in the diagnostic testing market is fragmented among numerous players.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in pain management, is characterized by intense competition, high R&D costs, and stringent regulatory requirements. There is a growing demand for non-opioid pain relief options due to the opioid crisis. The diagnostics market is also dynamic, driven by advancements in technology and the need for early and accurate disease detection.
Positioning
Scilex aims to position itself as a leader in non-opioid pain management by focusing on innovative delivery systems and novel compounds. Their acquisition strategy and focus on AI signal an intent to be at the forefront of pharmaceutical innovation. They also leverage strategic partnerships for their diagnostic offerings.
Total Addressable Market (TAM)
The global pain management market is a multi-billion dollar industry, with significant portions dedicated to chronic pain. The market for non-opioid analgesics is also growing rapidly. Scilex is a relatively small player within this vast TAM but is strategically targeting specific niches with its current and pipeline products. The diagnostic market TAM is also significant and growing.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management, addressing a significant market need.
- Strategic partnerships and acquisitions to expand product portfolio.
- Investment in AI for drug development efficiency.
- Existing commercialized product (Ztlido) and diagnostic partnerships.
Weaknesses
- Relatively small market share compared to established pharmaceutical giants.
- Dependence on pipeline products for future growth.
- Potential for high R&D failure rates.
- Limited brand recognition in certain therapeutic areas.
Opportunities
- Growing demand for non-opioid pain alternatives.
- Expansion of product indications and geographical reach.
- Advancements in AI and other technologies to accelerate drug development.
- Strategic acquisitions of promising drug candidates or technologies.
Threats
- Intense competition from established pharmaceutical companies and emerging biotech firms.
- Regulatory hurdles and delays in drug approval processes.
- Pricing pressures and reimbursement challenges.
- Patent expirations and the rise of generic competition.
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Amneal Pharmaceuticals LLC (AMRX)
- Supernus Pharmaceuticals, Inc. (SUPN)
Competitive Landscape
Scilex competes in a highly competitive landscape. Its competitive advantages lie in its specialized focus on non-opioid pain management, innovative delivery systems, and growing adoption of AI. However, it faces challenges from larger, well-established pharmaceutical companies with extensive R&D budgets, broad product portfolios, and strong market presence. The diagnostic segment also faces competition from numerous specialized companies.
Major Acquisitions
LumiraDx
- Year: 2023
- Acquisition Price (USD millions): 50
- Strategic Rationale: This acquisition aims to strengthen Scilex's diagnostic capabilities and expand its presence in the point-of-care diagnostics market. LumiraDx's technology and product portfolio are expected to complement Scilex's existing diagnostic offerings and create new revenue streams.
Growth Trajectory and Initiatives
Historical Growth: Scilex's growth has been driven by its strategic focus on pain management and its expansion through acquisitions and licensing. Revenue growth would be a key metric, alongside the progression of its product pipeline through clinical trials and regulatory approval.
Future Projections: Future growth is projected to be driven by the successful commercialization of its pipeline products and continued expansion of its diagnostic offerings. Analyst estimates would typically focus on revenue growth from new product launches and market penetration. The successful adoption of AI in its processes could also contribute to accelerated growth.
Recent Initiatives: Recent initiatives likely include advancing its clinical pipeline, exploring new therapeutic areas, and potentially further strategic partnerships or acquisitions to bolster its product portfolio and technological capabilities, particularly in AI.
Summary
Scilex Holding Company is strategically positioned in the growing non-opioid pain management market, leveraging its specialized products and AI integration. While it has a focused approach and some promising initiatives, it faces significant competition from larger pharmaceutical players. Its success hinges on the effective development and commercialization of its pipeline and the continued expansion of its diagnostic business. Careful financial management and strategic partnerships will be crucial for its long-term growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Company press releases and investor presentations
- Industry research reports on pain management and diagnostics markets
- Financial data aggregators
Disclaimers:
This JSON output is generated based on publicly available information and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data and financial figures are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-08 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.